Impact of renin-angiotensin system inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease
Renin-angiotensin system inhibitor (RASi) represents a cornerstone of guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF). However, RASi is often underutilized in patients with advanced chronic kidney disease (CKD) due to concerns regarding hyperkalemia and worsening renal...